A Study of NX-1607 in Adults With Advanced Malignancies

Study Summary

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

Conditions

Ovarian Cancer, Epithelial Gastric Cancer GastroEsophageal Junction (GEJ) Cancer Head and Neck Squamous Cell Carcinoma Metastatic or Unresectable Melanoma Non-small Cell Lung Cancer (NSCLC)Metastatic Castration-resistant Prostate Cancer (mCRPC)Malignant Pleural Mesothelioma (MPM)Triple Negative Breast Cancer (TNBC)Metastatic Urothelial Carcinoma Cervical Cancer Diffuse Large B Cell Lymphoma (DLBCL)Richter Transformation Microsatellite Stable Colorectal Carcinoma

Interventions / Drugs

NX-1607 Paclitaxel

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment345 participants

Primary Completion—

Lead SponsorNurix Therapeutics, Inc.

Data Retrieved2026-04-11 04:22:54.408594+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.